Baseline motor, behavioral, and cognitive characteristics of the COHORT population by group.

<p>Values are listed as mean (standard deviation) unless otherwise noted.</p><p>COHORT = Cooperative Huntington Observational Research Trial; HD = Huntington disease; (CAG)_n = cytosine-adenine-guanine repeat length in the <i>Huntingtin</i> allele; UHDRS = Unified Huntington's Disease Rating Scale.</p><p>*P-values refer to overall tests of heterogeneity across all six groups.</p><p>**For motor and behavioral measures, higher scores reflect greater impairment. For cognitive, independence, and functional measures, higher scores reflect less impairment.</p

Baseline demographics of the COHORT population by group.

<p>Values are listed as mean (standard deviation) unless otherwise noted.</p><p>COHORT = Cooperative Huntington Observational Research Trial; HD = Huntington disease; (CAG)_n = cytosine-adenine-guanine repeat length in the <i>Huntingtin</i> allele; UHDRS = Unified Huntington's Disease Rating Scale.</p><p>*P-values refer to overall tests of heterogeneity across all six groups.</p

Three most common medication classes used by participants in the COHORT study.

<p>*Combinations = products containing two or more active ingredients.</p

Reportable events within the COHORT study by group, 2006–2009.

<p>COHORT = Cooperative Huntington Observational Research Trial; HD = Huntington disease.</p

CAG repeat length of the shorter <i>Huntingtin</i> allele in different groups in the COHORT study.

<p>COHORT = Cooperative Huntington Observational Research Trial; HD = Huntington disease; (CAG)_n = cytosine-adenine-guanine trinucleotide repeat length.</p

Enrollment and baseline classification of COHORT research participants.

<p>Enrollment and baseline classification of COHORT research participants.</p

CAG repeat length of the larger <i>Huntingtin</i> allele in different groups in the COHORT study.

<p>CAG repeat length of the larger <i>Huntingtin</i> allele in different groups in the COHORT study.</p

Correlation between a) total, b) industry, and c) NIH research funding in 2005 and projected disease burden in 2015 for high income countries and the world.

<p>Correlation between a) total, b) industry, and c) NIH research funding in 2005 and projected disease burden in 2015 for high income countries and the world.</p

New Molecular Entities Approved by US Food and Drug Administration by Therapeutic Area, 1995–2005.

<p>New Molecular Entities Approved by US Food and Drug Administration by Therapeutic Area, 1995–2005.</p

Research support, sponsors, and FDA new drug approvals from 1995 – 2005 for a) all therapeutic areas, b) neuroscience research, c) oncology research, d) cardiovascular research, and e) endocrine research.

<p>Research support, sponsors, and FDA new drug approvals from 1995 – 2005 for a) all therapeutic areas, b) neuroscience research, c) oncology research, d) cardiovascular research, and e) endocrine research.</p